Paxlovid and Eliquis Interaction Management

Introduction to Management Strategies

The European Respiratory Review recommends considering switching to low molecular weight heparin (LMWH) during the 5-day Paxlovid treatment course to eliminate the drug interaction entirely, providing reliable anticoagulation without dose adjustment concerns 1
The European Respiratory Review suggests that if continuing apixaban is necessary, reducing the dose by 25% during Paxlovid therapy mitigates but does not eliminate the interaction risk, and requires careful calculation based on current apixaban dosing 2, 1

The European Respiratory Review advises exercising particular caution in patients with advanced age (>75 years) when co-administering Paxlovid and Eliquis 2
The European Respiratory Review recommends monitoring closely for bleeding signs and symptoms throughout the 5-day Paxlovid course and for 2-3 days after completion, especially in patients with concurrent antiplatelet therapy 3

The European Respiratory Review instructs patients to immediately report unusual bruising or bleeding, blood in urine or stool, prolonged bleeding from cuts, severe headache or dizziness, and coughing up blood or vomit that looks like coffee grounds when taking Paxlovid and Eliquis 1
The European Respiratory Review suggests that edoxaban represents the safest DOAC option with Paxlovid if switching anticoagulants is considered, as it demonstrates minimal clinically significant interactions and never requires dose adjustment with ritonavir-containing regimens 1, 3

Apixaban (Eliquis) is a substrate of both CYP3A4 and P-gp, making it vulnerable to significant drug interactions with inhibitors of these pathways, such as ritonavir, a component of Paxlovid, which can lead to increased apixaban blood levels and an elevated risk of bleeding complications, according to the American College of Cardiology 4
When a patient on Eliquis requires Paxlovid treatment, an alternative anticoagulant approach can be considered, such as temporarily switching to an alternative anticoagulant with fewer drug interactions during the Paxlovid treatment course, with low molecular weight heparin being an option, as suggested by Anaesthesia 5

The risk of interaction is particularly significant in patients with additional risk factors for bleeding or those with renal impairment, and careful monitoring for signs of bleeding is essential during co-administration, according to both the American College of Cardiology and Anaesthesia 4, 5
Patients should be educated about signs and symptoms of bleeding to report immediately, as recommended by the American College of Cardiology 4

Edoxaban, a factor Xa inhibitor, has similar concerns as with other factor Xa inhibitors when used with Paxlovid, as noted in the Journal of Hepatology 6